Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04221490

2019-06 TRISCEND Study

Prospective, multi-center study to assess safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Paul's Hospital Vancouver, Vancouver, British Columbia, Canada

Loading trial locations.

About this study

The study is a multi-center, prospective single arm study designed to evaluate the safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Functional or degenerative TR moderate or greater
  • Symptomatic despite medical therapy or prior HF hospitalization from TR
  • The Local Site Heart Team determines that the patient is appropriate for transcatheter tricuspid valve replacement

Key Exclusion Criteria:

  • Tricuspid valve anatomic contraindications
  • Need for emergent or urgent surgery or any planned cardiac surgery within the next 12 months
  • Hemodynamic instability
  • Refractory heart failure requiring advanced intervention
  • Currently participating in another investigational study in which the patient has not reached a primary endpoint

Treatment and study plan

Transcatheter Tricuspid Valve Replacement

Device

Replacement of the tricuspid valve through a transcatheter approach

Other names: Edwards EVOQUE Tricuspid Valve Replacement System

Primary outcomes

  1. Composite Major Adverse Events (MAEs)

    Time frame: 30 Days

    Composite of major adverse events (MAE) defined as cardiovascular mortality, myocardial infarction, stroke, renal complications requiring unplanned dialysis or renal replacement therapy, severe bleeding, unplanned or emergency tricuspid valve re-intervention, major access site and vascular complications, major access site and vascular complications, and device-related pulmonary embolism at 30 days.

  2. Device Success

    Time frame: Intraprocedural

    Study device is deployed as intended and the delivery system is successfully retrieved as intended at the time of the patient's exit from the cardiac catheterization laboratory.

  3. Procedure Success

    Time frame: Discharge (Up to 7 days post procedure)

    Device success without clinically significant paravalvular leak (PVL) on a transthoracic echocardiogram (assessed by the echo core lab) at time of discharge.

  4. Clinical Success

    Time frame: 30 Days

    Procedural success without MAEs at 30 days.

  5. Tricuspid Regurgitation Reduction

    Time frame: Discharge (Up to 7 days post procedure)

    Percentage of patients with at least 1 grade reduction in tricuspid regurgitation (TR) as measured by using a 5-grade classification system (mild, moderate, severe, massive, torrential). TR grade is assessed by an independent echocardiography core laboratory.

Secondary outcomes

  1. Tricuspid Regurgitation (TR) Grade

    Time frame: Baseline, 30 Days, 6 Months

    Tricuspid regurgitation (TR) is measured by transthoracic echocardiogram (TTE) at each visit using a 5-grade classification system (mild, moderate, severe, massive, torrential). TR grade is assessed by an independent echocardiography core laboratory.

  2. New York Heart Association (NYHA) Functional Class

    Time frame: Baseline, 30 Days, 6 Months

    NYHA Functional Classification - The stages of heart failure:

    Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest.

    Class IV - Severe limitations. Experiences symptoms even while at rest.

  3. Change in Six Minute Walk Test (6WMT) Distance

    Time frame: 30 Days, 6 Months

    Mean distance in meters walked during Six Minute Walk Test (6MWT) at each follow-up visit compared to baseline. 6MWT is a submaximal exercise test that measures the distance that a patient can walk on a flat surface in a period of 6 minutes.

  4. Change in Quality of Life Score as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: 30 Days, 6 Months

    Mean KCCQ score at each follow-up visit compared to baseline. The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores range from 0-100, in which higher scores reflect better health status.

  5. Change in Quality of Life as Measured by 36-Item Short Form Health Survey (SF-36) Mental Score

    Time frame: 30 Days, 6 Months

    Mean change in SF-36 mental score at each follow-up visit compared to baseline compared to baseline. The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

  6. Change in Quality of Life as Measured by 36-Item Short Form Health Survey (SF-36) Physical Score

    Time frame: 30 Days, 6 Months

    Mean change in SF-36 physical score at each follow-up visit compared to baseline. The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

  7. Change in Body Weight

    Time frame: 30 Days, 6 Months

    Mean change in body weight in kilograms at each follow-up visit compared to baseline.

  8. Change in Left Ankle Circumference

    Time frame: 30 Days, 6 Months

    Mean change in left ankle circumference in centimeters at each follow-up visit compared to baseline.

  9. Change in Right Ankle Circumference

    Time frame: 30 Days, 6 Months

    Mean change in right ankle circumference in centimeters at each follow-up visit compared to baseline.

  10. Edema Assessment By Visit

    Time frame: Baseline, 30 Days, 6 Months

    The edema grading scale measures how quickly the dimple goes back to normal (rebound) after a pitting test. The scale includes:

    Grade 1: Immediate rebound with 0 to 2 millimeter (mm) pit. Grade 2: Less than 15-second rebound with 3 to 4 mm pit. Grade 3: Rebound greater than 15 seconds but less than 60 seconds with 5 to 6 mm pit.

    Grade 4: Rebound between 2 to 3 minutes with an 8 mm pit.

Sponsors and collaborators

Lead sponsor

Edwards Lifesciences

Industry

Registry information

Official study title

Edwards EVOQUE Tricuspid Valve Replacement: Investigation of Safety and Clinical Efficacy After Replacement of Tricuspid Valve With Transcatheter Device

Important dates

Study start
2020
Primary completion
2024
Study completion
2029
First posted
Jan 9, 2020
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.